Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Hematol Oncol Stem Cell Ther
; 14(3): 192-198, 2021 Sep.
Article
em En
| MEDLINE
| ID: mdl-33290717
ABSTRACT
ROS proto-oncogene 1 (ROS1) encodes a type I integral membrane protein with tyrosine kinase activity and whose activating alterations are involved in the aggressiveness of several tumor types. Fusions involving ROS1 gene are present in 1-2% of lung adenocarcinomas and other solid tumors. Entrectinib, also known as RXDX-101, is a potent second-generation, multitarget oral inhibitor against NTRK1, NTRK2, NTRK3, ALK, and ROS1 with the ability to cross the blood-brain barrier. Results of Phase I and II trials have led the Food and Drug Administration to grant approval to entrectinib for the treatment of patients with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). In this review, we will describe the biology of ROS1, as well as results of the efficacy and safety of different clinical trials evaluating entrectinib in ROS1-positive NSCLC.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Benzamidas
/
Proteínas Tirosina Quinases
/
Proteínas Proto-Oncogênicas
/
Carcinoma Pulmonar de Células não Pequenas
/
Indazóis
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol Stem Cell Ther
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Peru